Browsing Tag
Depemokimab
2 posts
Can GSK’s Exdensur transform asthma biologics with just two doses per year?
GSK’s Exdensur is now FDA approved as the first biannual biologic for severe asthma. Explore what this means for rivals, payers, and global strategy.
Is GSK stock gearing up for a breakout? Q3 2025 results beat, guidance raised, CEO exits on a high
GSK upgrades 2025 guidance after strong Q3 results, driving a 6.57% stock surge. Find out how Specialty Medicines and Oncology powered this breakout.